 | • レポートコード：MRC2211A005 • 出版社/出版日：Transparency Market Research / 2022年9月 • レポート形態：英文、PDF、157ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界の腎臓病治療用ケトアナログ市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、市場見通し、用途別（慢性腎臓病、急性腎不全、その他）分析、エンドユーザー別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争分析などの内容を掲載しています。なお、当書には、Fresenius Kabi AG、RPG Life Sciences Ltd.、Alniche Life Sciences Pvt. Ltd.、La Renon Healthcare Pvt. Ltd.、Steadfast Medishield Pvt. Ltd.、Panacea Biotec、Element, Inc.、Ajanta Pharma Limited、Centaur Pharmaceuticals、Genix Lifescience Pvt. Ltd.などの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場動向 ・市場見通し ・世界の腎臓病治療用ケトアナログ市場規模：用途別 - 慢性腎臓病における市場規模 - 急性腎不全における市場規模 - その他用途における市場規模 ・世界の腎臓病治療用ケトアナログ市場規模：エンドユーザー別 - 病院薬局における市場規模 - 小売薬局における市場規模 - オンライン薬局における市場規模 ・世界の腎臓病治療用ケトアナログ市場規模：地域別 - 北米の腎臓病治療用ケトアナログ市場規模 - ヨーロッパの腎臓病治療用ケトアナログ市場規模 - アジア太平洋の腎臓病治療用ケトアナログ市場規模 - 中南米の腎臓病治療用ケトアナログ市場規模 - 中東・アフリカの腎臓病治療用ケトアナログ市場規模 ・競争分析 |
Ketoanalogue for Kidney Disease Market – Scope of Report
TMR’s report on the global ketoanalogue for kidney disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global ketoanalogue for kidney disease market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ketoanalogue for kidney disease market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the ketoanalogue for kidney disease market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ketoanalogue for kidney disease market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global ketoanalogue for kidney disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ketoanalogue for kidney disease market.
The report delves into the competitive landscape of the global ketoanalogue for kidney disease market. Key players operating in the global ketoanalogue for kidney disease market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ketoanalogue for kidney disease market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market ketoanalogue for kidney disease.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Market Overview
3.2. Introduction
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunity
4.4. Global Ketoanalogue for Kidney Disease Market Forecast
4.5. Global Ketoanalogue for Kidney Disease Market Outlook
5. Market Outlook
5.1. Average Pricing Per Product
5.2. Insights on Effect of Ketoanalogues on Chronic Kidney Disease Deterioration
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Ketoanalogue for Kidney Disease Market Analysis and Forecast, by Application
6.1. Introduction
6.2. Global Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
6.3. Global Ketoanalogue for Kidney Disease Market Forecast, by Application
6.3.1. Chronic Kidney Disease
6.3.1.1. Pre-dialysis
6.3.1.2. Dialysis Patients
6.3.2. Acute Renal Failure
6.3.2.1. Pre-renal
6.3.2.2. Post-renal
6.3.3. Others
7. Global Ketoanalogue for Kidney Disease Market Analysis and Forecast, by End-user
7.1. Introduction
7.2. Global Ketoanalogue for Kidney Disease Market Value Share Analysis, by End-user
7.3. Global Ketoanalogue for Kidney Disease Market Forecast, by End-user
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Ketoanalogue for Kidney Disease Market Analysis, by End-user
8. Global Ketoanalogue for Kidney Disease Market Analysis, by Region
8.1. Global Ketoanalogue for Kidney Disease Market Analysis, by Region
8.2. Global Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Region
8.3. Global Ketoanalogue for Kidney Disease Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America Ketoanalogue for Kidney Disease Market Analysis
9.1. North America Ketoanalogue for Kidney Disease Market Overview
9.2. North America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country
9.3. North America Ketoanalogue for Kidney Disease Market Forecast, by Country
9.3.1. U.S.
9.3.2. Canada
9.4. North America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
9.5. North America Ketoanalogue for Kidney Disease Market Forecast, by Application
9.5.1. Chronic Kidney Disease
9.5.1.1. Pre-dialysis
9.5.1.2. Dialysis Patients
9.5.2. Acute Renal Failure
9.5.2.1. Pre-renal
9.5.2.2. Post-renal
9.5.3. Others
9.6. North America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
9.7. North America Ketoanalogue for Kidney Disease Market Forecast, by End-user
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
10. Europe Ketoanalogue for Kidney Disease Market Analysis
10.1. Europe Ketoanalogue for Kidney Disease Market Overview
10.2. Europe Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.3. Europe Ketoanalogue for Kidney Disease Market Forecast, by Country/Sub-region
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Europe Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
10.5. Europe Ketoanalogue for Kidney Disease Market Forecast, by Application
10.5.1. Chronic Kidney Disease
10.5.1.1. Pre-dialysis
10.5.1.2. Dialysis Patients
10.5.2. Acute Renal Failure
10.5.2.1. Pre-renal
10.5.2.2. Post-renal
10.5.3. Others
10.6. Europe Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
10.7. Europe Ketoanalogue for Kidney Disease Market Forecast, by End-user
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
11. Asia Pacific Ketoanalogue for Kidney Disease Market Analysis
11.1. Asia Pacific Ketoanalogue for Kidney Disease Market Overview
11.2. Asia Pacific Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Asia Pacific Ketoanalogue for Kidney Disease Market Forecast, by Country/Sub-region
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. Australia & New Zealand
11.3.5. Taiwan
11.3.6. Rest of Asia Pacific
11.4. Asia Pacific Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
11.5. Asia Pacific Ketoanalogue for Kidney Disease Market Forecast, by Application
11.5.1. Chronic Kidney Disease
11.5.1.1. Pre-dialysis
11.5.1.2. Dialysis Patients
11.5.2. Acute Renal Failure
11.5.2.1. Pre-renal
11.5.2.2. Post-renal
11.5.3. Others
11.6. Asia Pacific Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
11.7. Asia Pacific Ketoanalogue for Kidney Disease Market Forecast, by End-user
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
12. Latin America Ketoanalogue for Kidney Disease Market Analysis
12.1. Latin America Ketoanalogue for Kidney Disease Market Overview
12.2. Latin America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Latin America Ketoanalogue for Kidney Disease Market Forecast, by Country/Sub-region
12.3.1. Brazil
12.3.2. Mexico
12.3.3. Rest of Latin America
12.4. Latin America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
12.5. Latin America Ketoanalogue for Kidney Disease Market Forecast, by Application
12.5.1. Chronic Kidney Disease
12.5.1.1. Pre-dialysis
12.5.1.2. Dialysis Patients
12.5.2. Acute Renal Failure
12.5.2.1. Pre-renal
12.5.2.2. Post-renal;
12.5.3. Others
12.6. Latin America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
12.7. Latin America Ketoanalogue for Kidney Disease Market Forecast, by End-user
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
13. Middle East & Africa Ketoanalogue for Kidney Disease Market Analysis
13.1. Middle East & Africa Ketoanalogue for Kidney Disease Market Overview
13.2. Middle East & Africa Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Middle East & Africa Ketoanalogue for Kidney Disease Market Forecast, by Country/Sub-region
13.3.1. GCC Countries
13.3.2. South Africa
13.3.3. Rest of Middle East & Africa
13.4. Middle East & Africa Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
13.5. Middle East & Africa Ketoanalogue for Kidney Disease Market Forecast, by Application
13.5.1. Chronic Kidney Disease
13.5.1.1. Pre-dialysis
13.5.1.2. Dialysis Patients
13.5.2. Acute Renal Failure
13.5.2.1. Pre-renal
13.5.2.2. Post-renal
13.5.3. Others
13.6. Middle East & Africa Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
13.7. Middle East & Africa Ketoanalogue for Kidney Disease Market Forecast, by End-user
13.8. Hospital Pharmacies
13.9. Retail Pharmacies
13.10. Online Pharmacies
14. Competitive Analysis
14.1. Competition Matrix
14.2. Company Profile
14.2.1. Fresenius Kabi AG
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Product Portfolio
14.2.1.3. Financial Overview
14.2.1.4. Strategic Overview
14.2.1.5. SWOT Analysis
14.2.2. RPG Life Sciences Ltd.
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Product Portfolio
14.2.2.3. Financial Overview
14.2.2.4. Strategic Overview
14.2.2.5. SWOT Analysis
14.2.3. Alniche Life Sciences Pvt. Ltd.
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Product Portfolio
14.2.3.3. Strategic Overview
14.2.3.4. SWOT Analysis
14.2.4. La Renon Healthcare Pvt. Ltd.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Product Portfolio
14.2.4.3. Strategic Overview
14.2.4.4. SWOT Analysis
14.2.5. Steadfast Medishield Pvt. Ltd.
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Product Portfolio
14.2.5.3. Strategic Overview
14.2.5.4. SWOT Analysis
14.2.6. Panacea Biotec
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Product Portfolio
14.2.6.3. Strategic Overview
14.2.6.4. SWOT Analysis
14.2.7. Element, Inc.
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Product Portfolio
14.2.7.3. Strategic Overview
14.2.7.4. SWOT Analysis
14.2.8. Ajanta Pharma Limited
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Product Portfolio
14.2.8.3. Financial Overview
14.2.8.4. Strategic Overview
14.2.8.5. SWOT Analysis
14.2.9. Centaur Pharmaceuticals
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Product Portfolio
14.2.9.3. Strategic Overview
14.2.9.4. SWOT Analysis
14.2.10. Genix Lifescience Pvt. Ltd.
14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.10.2. Product Portfolio
14.2.10.3. Strategic Overview
14.2.10.4. SWOT Analysis
Table 01: Average Pricing Per Product
Table 02: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 04: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 05: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 09: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 10: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 11: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 14: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 15: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 16: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 19: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 20: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 21: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 22: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 25: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 26: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 27: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 28: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 29: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 30: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 31: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 32: Business Overview (Fresenius Kabi AG)
Table 33: Business Overview (RPG Life Sciences Ltd.)
Table 34: Business Overview (Alniche Life Sciences Pvt. Ltd.)
Table 35: Business Overview (La Renon Healthcare Pvt. Ltd.)
Table 36: Business Overview (Steadfast Medishield Pvt. Ltd.)
Table 37: Business Overview (Panacea Biotec)
Table 38: Business Overview (Ajanta Pharma Limited)
Table 39: Business Overview (Centaur Pharmaceuticals)
Table 40: Business Overview (Genix Lifescience Pvt. Ltd.)
Table 41: Business Overview (United Biotech Pvt. Ltd.)